These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20458285)

  • 1. Biomarker-led adaptive trial blazes a trail in breast cancer.
    Allison M
    Nat Biotechnol; 2010 May; 28(5):383-4. PubMed ID: 20458285
    [No Abstract]   [Full Text] [Related]  

  • 2. Speed SPYing: adaptive clinical trials hit the gas.
    Zipkin M
    Nat Biotechnol; 2019 Sep; 37(9):975-977. PubMed ID: 31485040
    [No Abstract]   [Full Text] [Related]  

  • 3. [HER2 testing in breast cancer].
    Yoshimura K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
    [No Abstract]   [Full Text] [Related]  

  • 4. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW; Liu MC; Yee D; Yau C; van 't Veer LJ; Symmans WF; Paoloni M; Perlmutter J; Hylton NM; Hogarth M; DeMichele A; Buxton MB; Chien AJ; Wallace AM; Boughey JC; Haddad TC; Chui SY; Kemmer KA; Kaplan HG; Isaacs C; Nanda R; Tripathy D; Albain KS; Edmiston KK; Elias AD; Northfelt DW; Pusztai L; Moulder SL; Lang JE; Viscusi RK; Euhus DM; Haley BB; Khan QJ; Wood WC; Melisko M; Schwab R; Helsten T; Lyandres J; Davis SE; Hirst GL; Sanil A; Esserman LJ; Berry DA;
    N Engl J Med; 2016 Jul; 375(1):11-22. PubMed ID: 27406346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials. Experimental cancer therapies move to the front line.
    Couzin-Frankel J
    Science; 2012 Jan; 335(6066):282-3. PubMed ID: 22267789
    [No Abstract]   [Full Text] [Related]  

  • 6. What is the value of the 21 gene recurrence score in HER2-negative patients?
    Rosman M; Mylander WC; Tafra L
    J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
    [No Abstract]   [Full Text] [Related]  

  • 7. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
    Montemurro F
    Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
    [No Abstract]   [Full Text] [Related]  

  • 8. Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
    Pegram M; Perez EA; Piccart M; Spector N
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S131-41. PubMed ID: 18777952
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.
    Avan A; Avan A; Maftouh M; Ghayour Mobarhan M; Shahidsales S; Gholamin S
    J Clin Oncol; 2015 May; 33(15):1711-2. PubMed ID: 25870088
    [No Abstract]   [Full Text] [Related]  

  • 10. Utilisation of MR spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy.
    Leong KM; Lau P; Ramadan S
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):268-77. PubMed ID: 25913106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean).
    Colleoni M; Rotmensz N; Martinelli G; Gelber R; Coates A; Goldhirsch A
    Ann Oncol; 2004 Feb; 15(2):355-6. PubMed ID: 14760134
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
    Kane RC
    J Natl Cancer Inst; 2012 May; 104(9):717-8; author reply 718. PubMed ID: 22472306
    [No Abstract]   [Full Text] [Related]  

  • 13. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
    Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N
    Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
    Regan MM; Fleming GF; Walley B; Francis PA; Pagani O
    J Clin Oncol; 2019 Apr; 37(11):862-866. PubMed ID: 30811287
    [No Abstract]   [Full Text] [Related]  

  • 15. Ductal carcinoma in situ, complexities and challenges.
    Leonard GD; Swain SM
    J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of proteomic technologies in breast cancer research.
    Mazur MG; Pyatchanina TV
    Exp Oncol; 2016 Sep; 38(3):146-57. PubMed ID: 27685521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic endpoints in primary breast cancer.
    Di Cosimo S; Baselga J
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix21-3. PubMed ID: 17631590
    [No Abstract]   [Full Text] [Related]  

  • 19. Magnetic resonance imaging of the breast: opportunities to improve breast cancer management.
    Hylton N
    J Clin Oncol; 2005 Mar; 23(8):1678-84. PubMed ID: 15755976
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.